Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology”, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” To reinforce the competitiveness of our internal research efforts, we are partnering on promising products that complement our in-house portfolio and will help us achieve long-term growth.  With a long history of effective collaboration, our strategy involves partnering on specific aspects of research, development and/or commercialization.

Partner with Daiichi Sankyo

Daiichi Sankyo’s Core R&D Partnering Areas of interest are highlighted below but click this link to download a comprehensive listing of Daiichi Sankyo’s Partnering Areas of Interest.
• Oncology
• Specialty Medicine
• Technology and Related Research (ADC, oligonucleotides, Cell Therapy, Gene therapy, mRNA etc.)
• Vaccine

We expect our employees to demonstrate a passion and drive that is consistent with our company's strategy and vision. Do you share these values? Are you interested in learning how to partner with Daiichi Sankyo? Please contact us to start a conversation about how we can work together to improve patient lives through the development of high-quality pharmaceutical products. We have business development colleagues located globally, in Tokyo, Japan, in the United States (Basking Ridge, New Jersey), and in Europe (Munich, Germany). Please submit your licensing or alliance proposal for consideration.

Submit non-confidential proposal

Regional Commercial Interests

Japan

Late-stage or marketed products in Central Nervous System (CNS), Cardiovascular (CV) or Oncology for Japan commercialization

United States

Late-stage or marketed products/pipeline in Specialty Care for US commercialization

European Union

Late-stage or marketed products in Specialty Care for EU commercialization